PharmaCyte Biotech Inc (PMCB) — Net Asset Quality Index
PharmaCyte Biotech Inc (PMCB) has a Net Asset Quality Index of 70.5% as of January 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $55.87 Million minus total liabilities of $16.47 Million yields net assets of $39.40 Million. A higher index indicates a stronger, lower-leverage balance sheet. See PharmaCyte Biotech Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
PharmaCyte Biotech Inc Net Asset Quality Index Over Time (2004–2025)
This chart shows how PharmaCyte Biotech Inc's Net Asset Quality Index has evolved across 22 annual periods from 2004 to 2025. As of January 2026, the index stands at 70.5%, representing net assets of $39.40 Million against total assets of $55.87 Million USD. Explore PharmaCyte Biotech Inc (PMCB) cash conversion ratio to assess how effectively this company generates cash.
Annual Net Asset Quality Index for PharmaCyte Biotech Inc (2004–2025)
The table below presents the year-by-year Net Asset Quality Index for PharmaCyte Biotech Inc from 2004 to 2025, covering 22 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see PMCB market cap overview.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.1% | $51.89 Million | $55.17 Million | $3.28 Million | ▲ +28.1 pp |
| 2024 | 66.0% | $39.51 Million | $59.90 Million | $20.39 Million | ▼ -33.2 pp |
| 2023 | 99.2% | $72.69 Million | $73.28 Million | $586.58K | ▼ 0.0 pp |
| 2022 | 99.2% | $89.92 Million | $90.62 Million | $704.37K | ▲ +9.0 pp |
| 2021 | 90.2% | $6.68 Million | $7.40 Million | $724.78K | ▲ +7.7 pp |
| 2020 | 82.5% | $5.09 Million | $6.17 Million | $1.08 Million | ▼ -4.6 pp |
| 2019 | 87.2% | $5.04 Million | $5.78 Million | $742.85K | ▼ -2.8 pp |
| 2018 | 90.0% | $5.77 Million | $6.41 Million | $644.17K | ▼ -3.4 pp |
| 2017 | 93.3% | $8.09 Million | $8.67 Million | $580.25K | ▲ +2.2 pp |
| 2016 | 91.1% | $6.52 Million | $7.16 Million | $637.64K | ▲ +16.4 pp |
| 2015 | 74.7% | $5.94 Million | $7.95 Million | $2.01 Million | ▼ -21.3 pp |
| 2014 | 96.0% | $8.94 Million | $9.32 Million | $373.67K | ▲ +128.0 pp |
| 2013 | -32.0% | $-921.46K | $2.88 Million | $3.80 Million | ▲ +77.2 pp |
| 2012 | -109.2% | $-2.28 Million | $2.09 Million | $4.37 Million | ▲ +110.9 pp |
| 2011 | -220.1% | $-2.73 Million | $1.24 Million | $3.97 Million | ▼ -57.8 pp |
| 2010 | -162.3% | $-1.95 Million | $1.20 Million | $3.15 Million | ▼ -220.6 pp |
| 2009 | 58.3% | $3.99 Million | $6.84 Million | $2.85 Million | ▼ -39.3 pp |
| 2008 | 97.6% | $7.44 Million | $7.62 Million | $180.56K | ▲ +0.3 pp |
| 2007 | 97.3% | $4.29 Million | $4.41 Million | $118.81K | ▲ +11.4 pp |
| 2006 | 85.9% | $4.41 Million | $5.14 Million | $723.89K | ▲ +470.9 pp |
| 2005 | -385.0% | $-1.30 Million | $336.36K | $1.63 Million | ▼ -297.7 pp |
| 2004 | -87.3% | $-153.43K | $175.71K | $329.13K | — |